FDA & Camilia® Teething

FDA Press Release Regarding Teething Tablets & Gels

On Sept. 30, 2016, a press release titled “FDA warns against the use of homeopathic teething tablets and gels,” was distributed by the U.S. Food and Drug Administration (FDA). Parents who have questions about Camilia should read the press release on tablets and gels and know that Camilia is a single liquid dose. Read more about our ingredients.

Camilia has a remarkable safety record since it first debuted on the market more than 20 years ago. This medicine is relied upon by parents in many countries, including Canada and France, where it is a top-seller and has proven consumer satisfaction. As with all of Boiron’s over-the-counter medicines, Camilia’s marketing and production is regulated as a drug. It is manufactured according to the high standards of drug Good Manufacturing Practices, and conforms to the Homeopathic Pharmacopoeia of the United States.

Questions? Contact us at [email protected] or 1-800-BOIRON-1 (800-264-7661).

“Camilia has a remarkable safety record since it first debuted on the market more than 20 years ago.”
About Boiron
Boiron, world leader in homeopathic medicine, is a $852 million public company with 3,700 employees and distribution in 59 countries. It is best known for Oscillococcinum®, a top-selling flu medicine, and its Arnicare® line of pain relievers. For more than 80 years, Boiron has been committed to funding scientific research and educating the public and health care professionals on homeopathic medicine. As a pharmaceutical company, Boiron maintains the highest standards in manufacturing, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the United States and drug Good Manufacturing Practices.